The Tennis Anti-Doping Programme (TADP) has published its Q1 report for 2021. This report, like its predecessors (which are also available below), provides an overview of the TADP for the last quarter.
Click here to view the full report.
The Tennis Anti-Doping Programme is a comprehensive and internationally recognised drug-testing programme that applies to all players competing at Grand Slam tournaments and events sanctioned by the ITF, ATP, and WTA. Players are tested for substances prohibited by the World Anti-Doping Agency and, upon a finding that an Anti-Doping Rule Violation has been committed, sanctions are imposed in accordance with the requirements of the Tennis Anti-Doping Programme and World Anti-Doping Code.